Ezmekly becomes first approved EU therapy for NF1-PN in children and adults
21st July 2025 Uncategorised 0
EC grants conditional marketing authorisation to Merck and SpringWorks Therapeutics

More: Ezmekly becomes first approved EU therapy for NF1-PN in children and adults
Source: News
